M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback